COI/COC Governance for Multi-Site Programs


COI/COC Governance for Multi-Site Programs

Published on 01/12/2025

COI/COC Governance for Multi-Site Programs

Introduction to COI/COC in Biologics and Advanced Therapy Medicinal Products (ATMP)

The governance of Chain-of-Identity (COI) and Chain-of-Custody (COC) is paramount in the field of biologics and ATMP validation. These processes ensure the proper tracking and safeguarding of biological materials throughout their lifecycle, from collection to patient administration. As global regulations evolve, it’s essential for pharmaceutical professionals to implement robust governance frameworks that meet the stringent requirements of regulatory bodies such as the FDA, EMA, and MHRA.

This article serves as a comprehensive guide on the governance of COI and COC, detailing the necessary steps, best practices, and regulatory considerations associated with cold chain management and viral clearance validation in multi-site programs. Specifically, it will cover the implementation of viral clearance studies, the use of closed and single-use systems, and the importance of adhering to aseptic controls as outlined in Annex 1 of the EU GMP regulations.

Step 1: Understanding Chain-of-Identity and Chain-of-Custody

Chain-of-Identity and Chain-of-Custody are critical concepts in the management of biological materials. Here, we will define both terms and their relevance in the context of biologics and ATMPs.

Chain-of-Identity (COI) refers to the process that verifies that a biological product is uniquely identified throughout its lifecycle. This includes traceability from the source material to the final product administered to patients. It ensures that the right patient receives the right product, thereby minimizing risks associated with mix-ups or contamination.

Chain-of-Custody (COC), on the other hand, refers to the documented process that tracks the movement and handling of biological materials at all stages of development, production, and distribution. COC is particularly crucial during clinical trials and subsequent commercialization to monitor compliance with regulatory standards while ensuring the integrity and safety of the product.

Both COI and COC are vital for compliance with the applicable regulatory frameworks that govern biologics and ATMPs, including guidelines on quality assurance, validation, and traceability.

Step 2: Implementing Cold Chain Management

Cold chain management is a critical aspect of maintaining the integrity of biologic products. Temperature control is paramount in preventing degradation and ensuring the efficacy of ATMPs. Furthermore, failure to maintain appropriate temperatures can lead to significant product loss and compliance issues. Here’s how to implement a robust cold chain management system:

  • Temperature Mapping: Conduct a temperature mapping study to assess how different environments affect the biologics in question. Map the storage conditions across various physical sites to establish the temperature ranges required for effective chain management.
  • Equipment Qualification: Ensure that all equipment involved in storage and transportation (e.g., refrigerators, freezers, and transport containers) is qualified according to regulatory standards. This encompasses Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ).
  • Real-time Monitoring: Implement real-time temperature monitoring systems to continuously track the temperature of cold chain storage. This ensures that any deviations are immediately addressed, maintaining the integrity of the biologic materials.
  • Documentation and Record-Keeping: Maintain thorough documentation on cold chain management practices, including temperature logs, equipment qualification records, and maintenance schedules. This will support compliance with regulatory audits and inspections.

Step 3: Conducting Spiking Studies and Viral Clearance Validation

Viral clearance validation is a key component of the safety and efficacy assessment in the manufacture of biologics and ATMPs. This involves testing the ability of a manufacturing process to eliminate or inactivate viral contaminants. Spiking studies are a critical part of this process:

Spiking Studies: These studies involve intentionally introducing a known quantity of a virus into the sample during the manufacturing process to assess the effectiveness of the clearance methods. The goal is to demonstrate that the manufacturing process consistently reduces the viral load to acceptable levels.

  • Selecting the Appropriate Virus: The virus chosen for spiking studies should be representative of potential viral contaminants. Evaluate its characteristics, including its stability and resistance to various treatments.
  • Defining Acceptance Criteria: Establish clear acceptance criteria based on the regulatory guidance, such as ICH Q5A(R2). The criteria should outline the minimum required clearance factor for various viruses.
  • Execution of Studies: Carry out the studies under controlled conditions and ensure that all variables are documented. This includes time, temperature, and pH conditions during the viral inactivation steps.

Comprehensive documentation of spiking studies is essential for meeting regulatory expectations and ensuring product safety.

Step 4: Utilizing Closed and Single-Use Systems in Production

The adoption of closed and single-use systems has revolutionized the manufacturing of biopharmaceuticals, providing enhanced safety and flexibility in operations. These systems are particularly effective in minimizing contamination risks and streamlining processes. Here’s how to effectively implement these systems:

  • Closed Systems: Utilize closed systems for the handling and processing of biologic materials. This minimizes personnel exposure and reduces the potential for contamination. Ensure that these systems are validated for their intended uses and that aseptic controls are strictly adhered to.
  • Single-Use Systems: Embrace the use of single-use technologies to enhance operational efficiency. These systems are pre-sterilized and designed for one-time use, eliminating the need for extensive cleaning and validation processes. However, these systems still require validation for compatibility with the biological product.
  • Risk Assessment: Conduct a risk assessment to evaluate potential failure modes in the closed and single-use systems. This analysis should help identify critical points in the process where contamination might occur and establish robust controls to mitigate these risks.

Implementing these advanced systems in compliance with regulatory guidelines helps in maintaining the potency and identity of Critical Quality Attributes (CQAs), ensuring patient safety and product efficacy.

Step 5: Ensuring Compliance with Regulatory Standards

Compliance with regulatory standards is an ongoing challenge that requires a thorough understanding of applicable guidelines and a proactive approach to quality assurance. Here are best practices to ensure compliance:

  • Stay Updated with Regulatory Guidelines: Regularly review guidelines from entities such as the FDA, EMA, and ICH, which govern aspects like process validation and viral clearance. Staying informed about changes and updates ensures that the process remains compliant.
  • Training and Education: Provide continuous training for relevant staff on regulatory requirements related to COI/COC governance, viral clearance validation, and aseptic processing. This can enhance compliance and reduce the risk of violations.
  • Internal Audits: Conduct regular internal audits to assess compliance with established SOPs and regulatory requirements. Internal audits can help identify areas for improvement and ensure corrective actions are implemented promptly.

Step 6: Tailoring PPQ and CPV for ATMPs

Process Performance Qualification (PPQ) and Continued Process Verification (CPV) are essential elements in ensuring that manufacturing processes consistently yield products meeting predetermined quality criteria. Tailoring these protocols for ATMPs involves several key considerations:

  • Risk-Based Approach: Implement a risk-based approach when designing PPQ and CPV activities. This allows for the focus to be on areas of higher risk, enhancing the overall quality and compliance of the ATMPs produced.
  • Integration of CQAs: Ensure that Critical Quality Attributes (CQAs) identified during the product development phase are considered in the PPQ and CPV protocols. Develop meaningful metrics that reflect the product’s quality and safety.
  • Ongoing Monitoring: Establish continuous monitoring processes as part of CPV to ensure that any deviations in production are promptly identified and addressed. This proactive approach supports ongoing compliance and product integrity.

Collaborating closely with regulatory authorities during the development of these protocols can also facilitate alignment and acceptance of tailored approaches to validation.

Conclusion

COI and COC governance is a multifaceted process that plays a critical role in the successful validation of biologics and ATMPs. Through the implementation of stringent cold chain management, rigorous spiking studies, and the use of closed and single-use systems, pharmaceutical professionals can ensure compliance with regulatory standards and maintain product quality. By continuously monitoring and tailoring processes such as PPQ and CPV, organizations can enhance patient safety and meet the growing demands of the biologics market. Following these guidelines will not only help achieve compliance with the US FDA, EMA, and MHRA regulations but also lead to the successful delivery of high-quality biologic products to patients around the world.